SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AEROB)(OMX Nordic Exchange: AERO) announces that BlueCross BlueShield of Minnesota will retire its medical policy for FeNO testing effective August 27, 2012. BlueCross BlueShield of Minnesota has announced that it will retire their negative coverage policy regarding Fractional exhaled Nitric Oxide (FeNO) testing after a 90-day transition period. Following the transition period, exhaled nitric oxide measurement (CPT code 95012) will be covered for patients with asthma.
